Tagomics publishes a new approach to genome-wide epigenomic profiling

• Study published in ‘Cell Reports Methods’ demonstrates the strength of Tagomics’ platform for epigenomic biomarker discovery and applications in liquid biopsy
• Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts.

30 September 2025 -- Cambridge, UK -- Tagomics Ltd, a pioneering biomarker discovery and diagnostics company, today announced the publication of a peer-reviewed study in Cell Reports Methods, underpinning its epigenomic profiling technology, Active-Seq, the basis of Tagomics’ ActivaceTM platform. The paper, titled ‘Genome-wide profiling of unmodified DNA using methyltransferase-directed tagging and enrichment’, built on research from the University of Birmingham, describes Tagomics’ enzymatic approach to epigenomic profiling that targets unmethylated DNA for enrichment, and its application to biomarker identification and disease profiling in colorectal cancer patients.

Current gold standard approaches for assessing genome-wide DNA methylation levels are poorly suited to the challenge of working in liquid biopsy (blood) samples, limiting the performance of cell-free DNA based diagnostic tests. Addressing these limitations, the paper describes Active-Seq (Azide Click Tagging for In Vitro Epigenomic sequencing), a base conversion-free methodology that does not alter the underlying DNA sequence and provides a scalable and comprehensive solution for the discovery of novel biomarkers in liquid biopsy samples. Activace, built on the Active-Seq technology, is a streamlined workflow that incorporates sequencing library preparation with enrichment of unmethylated DNA. The workflow is compatible with low DNA input quantities, down to one nanogram, and has been optimised for the analysis of DNA methylation in cfDNA derived from liquid biopsy samples.

The published paper demonstrates application of Active-Seq for the detection of abnormal DNA methylation signals in a cohort of colorectal cancer patients, identifying thousands of hypomethylated and hypermethylated regions in tumour-derived tissue, both of which are associated with cancer. The study lays the groundwork for application of the approach to the deconvolution of the tissue of origin of cell-free DNA in blood, improving detection and characterisation of disease.

Dr Robert Neely, CSO and co-founder of Tagomics said: “This paper is an important milestone for Tagomics, demonstrating the groundbreaking technology that underpins our Activace and Interlace platforms. We show that our platform enables the sensitive detection of unmethylated genomic regions, which are key markers for DNA tissue of origin. We’re excited about the insight this is providing into the biology of cell-free DNA and are looking forward to seeing new applications for the platform in cancer diagnostics and patient safety monitoring for therapeutics.”

About Tagomics 
Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, has developed a novel multiomics platform, InterlaceTM, which offers a seamless solution for multiomic profiling to unlock disease-associated DNA biomarkers from a range of biological sources. Based in Cambridge, UK, Tagomics was launched in 2021 as a spin out from The University of Birmingham to build upon research led by Dr Robert Neely, the company’s Chief Scientific Officer. The company has since developed a suite of pioneering 'omics' technologies, including its Interlace multiomic platform, which seamlessly combines the Company’s novel approach to epigenomics (studying chemical 'switches' on the genome) with genomics (detecting mutations and other structural variants) and fragmentomics (the analysis of DNA fragmentation patterns in the blood). By integrating these methods and applying advanced data analysis and machine learning, the Tagomics Interlace platform can provide a 360° understanding of human health and disease. The company aims to discover novel disease markers and apply them to advance diagnostic and drug development. To support this mission, Tagomics has successfully raised over £8 million from investors including Calculus Capital, Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, Meltwind, OMX Ventures, and Start Codon. For more information about Tagomics, please visit: tagomics.com.